Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

Phase I/Ib Study of Parsaclisib (INCB50465), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (PaR-CHOP) Immunochemotherapy for Patients With Newly Diagnosed High Risk Diffuse Large B-Cell Lymphoma

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT04323956
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:31.639508+00:00
Published At
2026-02-02T00:00:00+00:00
Record Updated At
2026-02-02
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Ann Arbor Stage II Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage II Follicular Lymphoma", "Ann Arbor Stage II Marginal Zone Lymphoma", "Ann Arbor Stage III Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage III Follicular Lymphoma", "Ann Arbor Stage III Marginal Zone Lymphoma", "Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma", "Ann Arbor Stage IV Follicular Lymphoma", "Ann Arbor Stage IV Marginal Zone Lymphoma", "Diffuse Large B-Cell Lymphoma", "High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements", "High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements", "High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements", "Indolent Non-Hodgkin Lymphoma"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2026-02-02"
protocolSection.identificationModule.nctId
"NCT04323956"
protocolSection.identificationModule.officialTitle
"Phase I/Ib Study of Parsaclisib (INCB50465), Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (PaR-CHOP) Immunochemotherapy for Patients With Newly Diagnosed High Risk Diffuse Large B-Cell Lymphoma"
protocolSection.statusModule.overallStatus
"ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases
["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Ann Arbor Stage II Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage II Follicular Lymphoma (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage II Marginal Zone Lymphoma (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage III Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage III Follicular Lymphoma (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage III Marginal Zone Lymphoma (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage IV Follicular Lymphoma (protocolSection.conditionsModule.conditions)
  • Ann Arbor Stage IV Marginal Zone Lymphoma (protocolSection.conditionsModule.conditions)
  • Diffuse Large B-Cell Lymphoma (protocolSection.conditionsModule.conditions)
  • High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements (protocolSection.conditionsModule.conditions)
  • High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements (protocolSection.conditionsModule.conditions)
  • High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements (protocolSection.conditionsModule.conditions)
  • Indolent Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.